Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SynAct Pharma AB ( (SE:SYNACT) ) has issued an announcement.
SynAct Pharma AB released its interim report for the second quarter of 2025, highlighting significant events and financial developments. The company continues to focus on its research and development efforts in inflammatory diseases, which could impact its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation using melanocortin biology.
Average Trading Volume: 205,153
Technical Sentiment Signal: Sell
Current Market Cap: SEK929.2M
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.